Femoston Conti is an oral continuous combined type of Hormone Replacement Therapy (HRT). This type of HRT is more suitable for you if your last period was over twelve months ago. Femososton’s main components are:
- estradiol (a form of oestrogen)
- dydrogesterone (a form of progesterone).
The estradiol helps to make up for the body’s declining levels of oestrogen, as your ovaries produce less of it in the years approaching the menopause. Off-setting this balance can help reduce some of the more upsetting symptoms of the menopause, such as:
- irregular periods
- hot flushes
- night sweats
- mood swings
- vaginal dryness or itching.
It is worth noting that oestrogen stimulates the lining of the womb and in rare cases, this can lead to endometrial cancer. This is where dydrogesterone comes into action; it stops the estradiol’s womb stimulating effect, which reduces the risk of cancer.
The dydrogesterone levels in Femoston Conti are lower than those of cyclical combined HRT treatments, as Femoston Conti does not produce a monthly bleed, also called a withdrawal bleed.
If you are changing from cyclical HRT (such as Femoston 1/10 or 2/10), you should begin treatment the day after finishing the oestrogen plus progesterone phase.
Take one tablet daily. Swallow this tablet whole with a drink either with or without food.
Your tablet should be taken at around the same time each day; getting into a rhythm should help you to remember to take it.
If you forget to take a dose at your usual time the missed dose should be taken provided no more than 12 hours have elapsed since you last took a tablet. If your dose is more than 12 hours late, the forgotten dose should be skipped and your next dose should be taken at your usual time. If you take a double dose, this could lead to breakthrough bleeding.
Please note: if you ever need to have major surgery, please inform us as soon as you know, so that our doctor can advise you on whether to stop taking this medication.
Your need for HRT should be reviewed by your doctor at least once every twelve months.
The following side effects can affect individuals in different ways, it does not mean that all will be affected:
Very common (may affect more than 1 in 10 patients):
- abdominal pain
- back pain
- tender or painful breasts
Common (may affect up to 1 in 10 patients):
- vaginal thrush
- feeling depressed, nervousness
- migraine. If you have a migraine-like headache for the first time, stop taking Femoston-conti and see a doctor immediately
- feeling sick (nausea), vomiting, bloating (swelling of the abdomen), including wind (flatulence)
- allergic skin reactions
- menstrual disorder such as irregular bleeds, spotting, painful periods (dysmenorrhoea),
- heavier or less bleeding
- pelvic pain
- vaginal discharge
- feeling weak, tired or unwell
- swelling of your ankles, feet or fingers (peripheral oedema)
- weight increase
Uncommon (may affect up to 1 in 100 patients):
- cystitis-like symptoms
- growths in the womb (fibroids) get bigger
- hypersensitivity reactions such as dyspnoea (allergic asthma)
- change in sex drive
- blood clots in the legs or lungs (venous thromboembolism or pulmonary embolism)
- high blood pressure (hypertension)
- problems with your circulation (peripheral vascular disease)
- enlarged and tortuous (varicose) vein
- liver disorders, sometimes with yellowing of the skin (jaundice), feeling weak (asthenia) or generally feeling unwell (malaise), and abdominal pain. If you notice yellowing of the skin or the whites of your eyes, stop taking Femoston-conti and see a doctor immediately.
- gallbladder disease
- swelling of your breasts
- pre-menstrual syndrome (PMS)
- weight decrease
The side effects listed above may not include all of the side effects reported by the medicine's manufacturer. For more information about any other possible risks associated with Femoston Conti, please read the information provided with the medicine or consult your doctor or pharmacist.
Femoston should be used with caution if you have:
- fibroids inside your womb
- a growth of womb lining outside your womb (endometriosis) or a history of excessive growth of the womb lining (endometrial hyperplasia)
- increased risk of developing blood clots (thrombosis)
- increased risk of getting an oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)
- high blood pressure
- a liver disorder, such as a benign liver tumour
- migraine or severe headaches
- a disease of the immune system that affects many organs of the body (systemic lupus erythematosus, SLE)
- a disease affecting the eardrum and hearing (otosclerosis)
- a very high level of fat in your blood (triglycerides)
- fluid retention due to cardiac or kidney problems
Femoston should not be used if you:
- have or have ever had breast cancer, or if you are suspected of having it
- have cancer which is sensitive to oestrogens, such as cancer of the womb lining (endometrium), or if you are suspected of having it
- have any unexplained vaginal bleeding
- have excessive thickening of the womb lining (endometrial hyperplasia) that is not being treated
- have or have ever had a blood clot in a vein (thrombosis), such as in the legs (deep venous
- thrombosis) or the lungs (pulmonary embolism)
- have a blood clotting disorder (such as protein C, protein S, or antithrombin deficiency)
- have or recently have had a disease caused by blood clots in the arteries, such as a heart attack, stroke or angina
- have or have ever had a liver disease and your liver function tests have not returned to normal
- have a rare blood problem called “porphyria” which is passed down in families (inherited)
Femoston should not be used if you are allergic to one or any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy. If you feel you have experienced an allergic reaction, stop using this medicine and inform your doctor or pharmacist immediately.
The patient information leaflet (PIL) is a leaflet containing specific information about medical conditions, doses and side effects. You can download a copy of the PIL here:
Patient Info Leaflet